Hormone receptor-positive (HR + )/human epidermal growth factor receptor 2-negative (HER2-) breast cancer is known to be non-responsive to chemotherapy; however, lymph node positivity (LN+ ) is an indicator for chemotherapy. Here, ERBB2 is linked to breast carcinoma.